Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 568-575

  Buydens Branchey, Laure ^a   Branchey, Marc ^a   Hibbeln, Joseph R ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Anger; Anxiety; Docosahexaenoic acid (DHA); Eicosapentaenoic acid (EPA); Supplementation

Indexed keywords

ANTIDEPRESSANT AGENT; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; METHADONE; OMEGA 3 FATTY ACID;

AGGRESSION; ANGER; ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; MALE; SCORING SYSTEM; SUBSTANCE ABUSE;

AGGRESSION; AMBULATORY CARE; ANGER; ANXIETY DISORDERS; DIETARY FATS, UNSATURATED; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; ENERGY INTAKE; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FOLLOW-UP STUDIES; HOSTILITY; HUMANS; MALE; PILOT PROJECTS; PLACEBOS; QUESTIONNAIRES; SOYBEAN OIL; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 38749137406     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.10.020     Document Type: Article

References (42)

1. Alessandri J.M., Guesnet P., Vancassel S., Astorg P., Denis I., Langelier B., et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 44 (2004) 509-538
2. Buydens-Branchey L., and Branchey M. N-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 26 (2006) 661-665
3. Buydens-Branchey L, Branchey M. Long chain n-3 polyunsaturated fatty acids treatment decreases feelings of anger in substance abusers. Psychiatry Res in press. doi:10.1016/j.psychres.2007.01.004.
4. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. (1988), Lawrence Earlbaum, Hillsdale, NJ
5. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM IV Axis I Disorders (SCID-I) (1997), American Psychiatric Press, Washington, DC
6. Frangou S., Lewis M., and McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188 (2006) 46-50
7. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67 (2006) 1954-1967
8. Fux M., Benjamin J., and Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 38 (2004) 323-325
9. Gesch C.B., Hammond S.M., Hampson S.E., Hampson S.E., Eves A., Crowder M.J., et al. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behavior of young adult prisoners: randomized, placebo-controlled trial. Br J Psychiatry 181 (2002) 22-28
10. Green P., Hermesh H., Monselise A., Marom S., Presburger G., and Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 16 (2006) 107-113
11. Hamazaki T., Sawazaki S., Itomura M., Asaoka E., Nagao Y., Nishimura N., et al. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 97 (1996) 1129-1133
12. Hamazaki T., Sawazaki S., Nagao Y., Kuwamori T., Yazawa K., Mizushima Y., et al. Docosahexaenoic acid does not affect aggression of normal volunteers under nonstressful conditions. A randomized, placebo-controlled, double-blind study. Lipids 33 (1998) 663-667
13. Hamazaki T., Thienprasert A., Kheovichai K., Samuhaseneetoo S., Nagasawa T., and Watanabe S. The effect of docosahexaenoic acid on aggression in elderly Thai subjects - a placebo-controlled double-blind study. Nutr Neurosci 5 (2002) 37-41
14. Hibbeln J.R. Fish consumption and major depression [letter]. Lancet 35 (1998) 1213
15. Hibbeln J.R. Seafood consumption and homicide mortality: a cross-national ecological analysis. World Rev Nutr Diet 88 (2001) 41-46
16. Hibbeln J.R. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord 69 (2002) 15-29
17. Hibbeln J.R., Linnoila M., Umhau J.C., Rawlings R., George D.T., and Salem Jr. N. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 44 (1998) 235-242
18. Hibbeln J.R., Nieminen L.R., Blasbalg T.L., Riggs J.A., and Lands W.E. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 83 Suppl 6 (2006) 1483S-1493S
19. International Society for the Study of Fatty Acids and Lipids. Recommendations for Dietary Intake of Polyunsaturated Fatty Acids in Healthy Adults (2004), Brighton, UK
20. Iribarren C., Markovitz J.H., Jacobs Jr. D.R., Schreiner P.J., Daviglus M., and Hibbeln J.R. Dietary intake of n-3, n-6 fatty acids and fish: Relationship with hostility in young adults - the CARDIA study. Eur J Clin Nutr 58 (2004) 24-31
21. Keck Jr. P.E., Mintz J., McElroy S.L., Freeman M.P., Suppes T., Frye M.A., et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60 (2006) 1020-1022
22. Kim S.Y., Breslow R.A., Ahn J., and Salem Jr. N. Alcohol consumption and fatty acid intakes in the 2001-2002 National Health and Nutrition Examination Survey. Alcohol Clin Exp Res 31 (2007) 1407-1414
23. Lands W.E.M., Pawlosky R.J., and Salem Jr. N. Alcoholism, antioxidant status and essential fatty acids. In: Pappas A.M. (Ed). Antioxidants in Nutrition and Health (1998), CRC Press, Boca Raton, FL 299-344
24. Masood A., Stark K.D., and Salem N. A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies. J Lipid Res 46 (2005) 2299-2305
25. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 9 (1992) 199-213
26. McNair D.M., Lorr M., and Droppleman L.F. Manual for the Profile of Mood States (1971), Educational Testing Service, San Diego
27. National Cancer Institute. US National Institutes of Health. Diet History Questionnaire DHQ-1 2002 (2002). http://riskfactor.cancer.gov/DHQ [Available at: http://riskfactor.cancer.gov/DHQ. Accessed Jun 15, 2007]
28. Nemets B., Stahl Z., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159 (2002) 477-479
29. Noaghiul S., and Hibbeln J.R. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 160 (2003) 2222-2227
30. Peet M., and Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59 (2002) 913-919
31. Salem Jr. N., and Olsson N.U. Abnormalities in essential fatty acid status in alcoholism. In: Mostofsky D.I., and Yehuda S. (Eds). Handbook of Essential Fatty Acid Biology: Biochemistry, Physiology, and Behavioral Neurobiology (1997), Humana Press, Totowa, NJ 67-87
32. Salem Jr. N., Litman B., Kim H.Y., and Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36 (2001) 945-959
33. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. Coll Nutr 21 (2002) 495-505
34. Sinclair A.J., Begg D., Mathai M., and Weisinger R.S. Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac J Clin Nutr 16 Suppl 1 (2007) 391-397
35. Song C., Leonard B.E., and Horrobin D.F. Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats. Stress 7 (2004) 43-54
36. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56 (1999) 407-412
37. Su K.P., Huang S.Y., Chiu C.C., and Shen W.W. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 13 (2003) 267-271
38. U.S. Department of Agriculture. Agricultural Research Service. USDA National Nutrient Database for Standard Reference, Release 17. Nutrient Data Laboratory Home Page (2004). http://www.nal.usda.gov/fnic/foodcomp [Available at: http://www.nal.usda.gov/fnic/foodcomp. Accessed Jun 15, 2007]
39. Virkkunen M.E., Horrobin D.F., Jenkins D.K., and Manku M.S. Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent, and impulsive offenders. Biol Psychiatry 22 (1987) 1087-1096
40. Yehuda S., Rabinovitz S., and Mostofsky D.I. Mixture of essential fatty acids lowers test anxiety. Nutr Neurosci 8 (2005) 265-267
41. Young G.S., and Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 45 (2005) 1-28.
42. Zanarini M.C., and Frankenburg F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160 (2003) 167-169